Plexera Bioscience Announces Agreement with Leading Therapeutic Antibody Company

Plexera Biosciences LLC, a wholly owned subsidiary of Lumera Corporation (NASDAQ:LMRA), announced today that it has signed an Early Access Agreement with an undisclosed leading therapeutic antibody company as its first participant in the company’s Early Access Program.

Source: Lumera